お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は泌尿器系薬剤市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは泌尿器系薬剤の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の泌尿器系薬剤市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは泌尿器系薬剤のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に泌尿器系薬剤市場を分類しています。本研究に含まれる主な企業は：Johnson & Johnson、Bayer、Pfizer、GSK、Boehringer Ingelheim、Roche、Novartis、AstraZeneca、Dr. Reddy’s Laboratories、Mylan、Sun Pharma、Cipla、Merck、Cubist Pharmaceuticals、Abbott Laboratories、Eli Lilly、Melinta Therapeutics、Sanofi、Daiichi Sankyo、Lupin、Apogepha、Astellas Pharma、Dr. Dunner、Kowa、Jiangxi Jimin Kexin Jinshuibao Pharmaceutical、Tianjin Tongrentang Group、Jiangsu Hengrui Pharmaceutical、Hunan Qianjin Xiang River Pharmaceutical、Kunming Jida Pharmaceutical、Jiangsu Lianhuan Pharmaceutical

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Injection
    Tablets
    Capsule
    Suppository
    Granules
    Powder
    Pills
    Cream
    Others

用途別の市場セグメント：
    Kidney Disease Medication
    Medication For Prostate Disease
    Male Dysfunction
    Lithotripsy Drug
    Others

本レポートの詳細内容
世界の泌尿器系薬剤市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、泌尿器系薬剤タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の泌尿器系薬剤収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の泌尿器系薬剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、泌尿器系薬剤市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

泌尿器系薬剤のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：泌尿器系薬剤のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：泌尿器系薬剤の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章泌尿器系薬剤企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：泌尿器系薬剤の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：泌尿器系薬剤の主要企業の概要を提供し、製品の説明と仕様、泌尿器系薬剤の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Urinary System Drugs Market
The global Urinary System Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Urinary System Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Urinary System Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Urinary System Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Urinary System Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Urinary System Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Urinary System Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Johnson & Johnson, Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche, Novartis, AstraZeneca and Dr. Reddy’s Laboratories, etc.
Market Segmentation
By Company
    Johnson & Johnson
    Bayer
    Pfizer
    GSK
    Boehringer Ingelheim
    Roche
    Novartis
    AstraZeneca
    Dr. Reddy’s Laboratories
    Mylan
    Sun Pharma
    Cipla
    Merck
    Cubist Pharmaceuticals
    Abbott Laboratories
    Eli Lilly
    Melinta Therapeutics
    Sanofi
    Daiichi Sankyo
    Lupin
    Apogepha
    Astellas Pharma
    Dr. Dunner
    Kowa
    Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
    Tianjin Tongrentang Group
    Jiangsu Hengrui Pharmaceutical
    Hunan Qianjin Xiang River Pharmaceutical
    Kunming Jida Pharmaceutical
    Jiangsu Lianhuan Pharmaceutical

Segment by Type
    Injection
    Tablets
    Capsule
    Suppository
    Granules
    Powder
    Pills
    Cream
    Others

Segment by Application
    Kidney Disease Medication
    Medication For Prostate Disease
    Male Dysfunction
    Lithotripsy Drug
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Urinary System Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary System Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Urinary System Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Urinary System Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Injection
    Table 3. Key Players of Tablets
    Table 4. Key Players of Capsule
    Table 5. Key Players of Suppository
    Table 6. Key Players of Granules
    Table 7. Key Players of Powder
    Table 8. Key Players of Pills
    Table 9. Key Players of Cream
    Table 10. Key Players of Others
    Table 11. Global Urinary System Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 12. Global Urinary System Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 13. Global Urinary System Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 14. Global Urinary System Drugs Market Share by Region (2019-2024)
    Table 15. Global Urinary System Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 16. Global Urinary System Drugs Market Share by Region (2025-2030)
    Table 17. Urinary System Drugs Market Trends
    Table 18. Urinary System Drugs Market Drivers
    Table 19. Urinary System Drugs Market Challenges
    Table 20. Urinary System Drugs Market Restraints
    Table 21. Global Urinary System Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 22. Global Urinary System Drugs Revenue Share by Players (2019-2024)
    Table 23. Global Top Urinary System Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2023)
    Table 24. Global Urinary System Drugs Industry Ranking 2022 VS 2023 VS 2024
    Table 25. Global 5 Largest Players Market Share by Urinary System Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 26. Global Key Players of Urinary System Drugs, Headquarters and Area Served
    Table 27. Global Key Players of Urinary System Drugs, Product and Application
    Table 28. Global Key Players of Urinary System Drugs, Product and Application
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 31. Global Urinary System Drugs Revenue Market Share by Type (2019-2024)
    Table 32. Global Urinary System Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 33. Global Urinary System Drugs Revenue Market Share by Type (2025-2030)
    Table 34. Global Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 35. Global Urinary System Drugs Revenue Share by Application (2019-2024)
    Table 36. Global Urinary System Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 37. Global Urinary System Drugs Revenue Share by Application (2025-2030)
    Table 38. North America Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 39. North America Urinary System Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 40. North America Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 41. North America Urinary System Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 42. North America Urinary System Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. North America Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 44. North America Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 45. Europe Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 46. Europe Urinary System Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 47. Europe Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 48. Europe Urinary System Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Europe Urinary System Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 50. Europe Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 51. Europe Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 52. China Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 53. China Urinary System Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 54. China Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 55. China Urinary System Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 56. Asia Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Asia Urinary System Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Asia Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Asia Urinary System Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Asia Urinary System Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Asia Urinary System Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 62. Asia Urinary System Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 66. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 67. Middle East, Africa, and Latin America Urinary System Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 68. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 69. Middle East, Africa, and Latin America Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 70. Johnson & Johnson Company Details
    Table 71. Johnson & Johnson Business Overview
    Table 72. Johnson & Johnson Urinary System Drugs Product
    Table 73. Johnson & Johnson Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 74. Johnson & Johnson Recent Developments
    Table 75. Bayer Company Details
    Table 76. Bayer Business Overview
    Table 77. Bayer Urinary System Drugs Product
    Table 78. Bayer Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 79. Bayer Recent Developments
    Table 80. Pfizer Company Details
    Table 81. Pfizer Business Overview
    Table 82. Pfizer Urinary System Drugs Product
    Table 83. Pfizer Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 84. Pfizer Recent Developments
    Table 85. GSK Company Details
    Table 86. GSK Business Overview
    Table 87. GSK Urinary System Drugs Product
    Table 88. GSK Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 89. GSK Recent Developments
    Table 90. Boehringer Ingelheim Company Details
    Table 91. Boehringer Ingelheim Business Overview
    Table 92. Boehringer Ingelheim Urinary System Drugs Product
    Table 93. Boehringer Ingelheim Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 94. Boehringer Ingelheim Recent Developments
    Table 95. Roche Company Details
    Table 96. Roche Business Overview
    Table 97. Roche Urinary System Drugs Product
    Table 98. Roche Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 99. Roche Recent Developments
    Table 100. Novartis Company Details
    Table 101. Novartis Business Overview
    Table 102. Novartis Urinary System Drugs Product
    Table 103. Novartis Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 104. Novartis Recent Developments
    Table 105. AstraZeneca Company Details
    Table 106. AstraZeneca Business Overview
    Table 107. AstraZeneca Urinary System Drugs Product
    Table 108. AstraZeneca Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 109. AstraZeneca Recent Developments
    Table 110. Dr. Reddy’s Laboratories Company Details
    Table 111. Dr. Reddy’s Laboratories Business Overview
    Table 112. Dr. Reddy’s Laboratories Urinary System Drugs Product
    Table 113. Dr. Reddy’s Laboratories Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 114. Dr. Reddy’s Laboratories Recent Developments
    Table 115. Mylan Company Details
    Table 116. Mylan Business Overview
    Table 117. Mylan Urinary System Drugs Product
    Table 118. Mylan Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 119. Mylan Recent Developments
    Table 120. Sun Pharma Company Details
    Table 121. Sun Pharma Business Overview
    Table 122. Sun Pharma Urinary System Drugs Product
    Table 123. Sun Pharma Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 124. Sun Pharma Recent Developments
    Table 125. Cipla Company Details
    Table 126. Cipla Business Overview
    Table 127. Cipla Urinary System Drugs Product
    Table 128. Cipla Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 129. Cipla Recent Developments
    Table 130. Merck Company Details
    Table 131. Merck Business Overview
    Table 132. Merck Urinary System Drugs Product
    Table 133. Merck Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 134. Merck Recent Developments
    Table 135. Cubist Pharmaceuticals Company Details
    Table 136. Cubist Pharmaceuticals Business Overview
    Table 137. Cubist Pharmaceuticals Urinary System Drugs Product
    Table 138. Cubist Pharmaceuticals Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 139. Cubist Pharmaceuticals Recent Developments
    Table 140. Abbott Laboratories Company Details
    Table 141. Abbott Laboratories Business Overview
    Table 142. Abbott Laboratories Urinary System Drugs Product
    Table 143. Abbott Laboratories Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 144. Abbott Laboratories Recent Developments
    Table 145. Eli Lilly Company Details
    Table 146. Eli Lilly Business Overview
    Table 147. Eli Lilly Urinary System Drugs Product
    Table 148. Eli Lilly Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 149. Eli Lilly Recent Developments
    Table 150. Melinta Therapeutics Company Details
    Table 151. Melinta Therapeutics Business Overview
    Table 152. Melinta Therapeutics Urinary System Drugs Product
    Table 153. Melinta Therapeutics Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 154. Melinta Therapeutics Recent Developments
    Table 155. Sanofi Company Details
    Table 156. Sanofi Business Overview
    Table 157. Sanofi Urinary System Drugs Product
    Table 158. Sanofi Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 159. Sanofi Recent Developments
    Table 160. Daiichi Sankyo Company Details
    Table 161. Daiichi Sankyo Business Overview
    Table 162. Daiichi Sankyo Urinary System Drugs Product
    Table 163. Daiichi Sankyo Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 164. Daiichi Sankyo Recent Developments
    Table 165. Lupin Company Details
    Table 166. Lupin Business Overview
    Table 167. Lupin Urinary System Drugs Product
    Table 168. Lupin Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 169. Lupin Recent Developments
    Table 170. Apogepha Company Details
    Table 171. Apogepha Business Overview
    Table 172. Apogepha Urinary System Drugs Product
    Table 173. Apogepha Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 174. Apogepha Recent Developments
    Table 175. Astellas Pharma Company Details
    Table 176. Astellas Pharma Business Overview
    Table 177. Astellas Pharma Urinary System Drugs Product
    Table 178. Astellas Pharma Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 179. Astellas Pharma Recent Developments
    Table 180. Dr. Dunner Company Details
    Table 181. Dr. Dunner Business Overview
    Table 182. Dr. Dunner Urinary System Drugs Product
    Table 183. Dr. Dunner Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 184. Dr. Dunner Recent Developments
    Table 185. Kowa Company Details
    Table 186. Kowa Business Overview
    Table 187. Kowa Urinary System Drugs Product
    Table 188. Kowa Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 189. Kowa Recent Developments
    Table 190. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Company Details
    Table 191. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Business Overview
    Table 192. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Urinary System Drugs Product
    Table 193. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 194. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Developments
    Table 195. Tianjin Tongrentang Group Company Details
    Table 196. Tianjin Tongrentang Group Business Overview
    Table 197. Tianjin Tongrentang Group Urinary System Drugs Product
    Table 198. Tianjin Tongrentang Group Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 199. Tianjin Tongrentang Group Recent Developments
    Table 200. Jiangsu Hengrui Pharmaceutical Company Details
    Table 201. Jiangsu Hengrui Pharmaceutical Business Overview
    Table 202. Jiangsu Hengrui Pharmaceutical Urinary System Drugs Product
    Table 203. Jiangsu Hengrui Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 204. Jiangsu Hengrui Pharmaceutical Recent Developments
    Table 205. Hunan Qianjin Xiang River Pharmaceutical Company Details
    Table 206. Hunan Qianjin Xiang River Pharmaceutical Business Overview
    Table 207. Hunan Qianjin Xiang River Pharmaceutical Urinary System Drugs Product
    Table 208. Hunan Qianjin Xiang River Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 209. Hunan Qianjin Xiang River Pharmaceutical Recent Developments
    Table 210. Kunming Jida Pharmaceutical Company Details
    Table 211. Kunming Jida Pharmaceutical Business Overview
    Table 212. Kunming Jida Pharmaceutical Urinary System Drugs Product
    Table 213. Kunming Jida Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 214. Kunming Jida Pharmaceutical Recent Developments
    Table 215. Jiangsu Lianhuan Pharmaceutical Company Details
    Table 216. Jiangsu Lianhuan Pharmaceutical Business Overview
    Table 217. Jiangsu Lianhuan Pharmaceutical Urinary System Drugs Product
    Table 218. Jiangsu Lianhuan Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
    Table 219. Jiangsu Lianhuan Pharmaceutical Recent Developments
    Table 220. Research Programs/Design for This Report
    Table 221. Key Data Information from Secondary Sources
    Table 222. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Urinary System Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Urinary System Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Injection Features
    Figure 4. Tablets Features
    Figure 5. Capsule Features
    Figure 6. Suppository Features
    Figure 7. Granules Features
    Figure 8. Powder Features
    Figure 9. Pills Features
    Figure 10. Cream Features
    Figure 11. Others Features
    Figure 12. Global Urinary System Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 13. Global Urinary System Drugs Market Share by Application: 2023 VS 2030
    Figure 14. Kidney Disease Medication Case Studies
    Figure 15. Medication For Prostate Disease Case Studies
    Figure 16. Male Dysfunction Case Studies
    Figure 17. Lithotripsy Drug Case Studies
    Figure 18. Others Case Studies
    Figure 19. Urinary System Drugs Report Years Considered
    Figure 20. Global Urinary System Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 21. Global Urinary System Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 22. Global Urinary System Drugs Market Share by Region: 2023 VS 2030
    Figure 23. Global Urinary System Drugs Market Share by Players in 2023
    Figure 24. Global Top Urinary System Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2023)
    Figure 25. The Top 10 and 5 Players Market Share by Urinary System Drugs Revenue in 2023
    Figure 26. North America Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. North America Urinary System Drugs Market Share by Type (2019-2030)
    Figure 28. North America Urinary System Drugs Market Share by Application (2019-2030)
    Figure 29. North America Urinary System Drugs Market Share by Country (2019-2030)
    Figure 30. United States Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Canada Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Europe Urinary System Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 33. Europe Urinary System Drugs Market Share by Type (2019-2030)
    Figure 34. Europe Urinary System Drugs Market Share by Application (2019-2030)
    Figure 35. Europe Urinary System Drugs Market Share by Country (2019-2030)
    Figure 36. Germany Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. France Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. U.K. Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Italy Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Russia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Nordic Countries Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Urinary System Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 43. China Urinary System Drugs Market Share by Type (2019-2030)
    Figure 44. China Urinary System Drugs Market Share by Application (2019-2030)
    Figure 45. Asia Urinary System Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 46. Asia Urinary System Drugs Market Share by Type (2019-2030)
    Figure 47. Asia Urinary System Drugs Market Share by Application (2019-2030)
    Figure 48. Asia Urinary System Drugs Market Share by Region (2019-2030)
    Figure 49. Japan Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. South Korea Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. China Taiwan Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Southeast Asia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. India Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Australia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Middle East, Africa, and Latin America Urinary System Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 56. Middle East, Africa, and Latin America Urinary System Drugs Market Share by Type (2019-2030)
    Figure 57. Middle East, Africa, and Latin America Urinary System Drugs Market Share by Application (2019-2030)
    Figure 58. Middle East, Africa, and Latin America Urinary System Drugs Market Share by Country (2019-2030)
    Figure 59. Brazil Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Mexico Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 61. Turkey Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 62. Saudi Arabia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 63. Israel Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 64. GCC Countries Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 65. Johnson & Johnson Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 66. Bayer Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 67. Pfizer Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 68. GSK Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 69. Boehringer Ingelheim Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 70. Roche Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 71. Novartis Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 72. AstraZeneca Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 73. Dr. Reddy’s Laboratories Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 74. Mylan Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 75. Sun Pharma Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 76. Cipla Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 77. Merck Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 78. Cubist Pharmaceuticals Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 79. Abbott Laboratories Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 80. Eli Lilly Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 81. Melinta Therapeutics Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 82. Sanofi Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 83. Daiichi Sankyo Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 84. Lupin Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 85. Apogepha Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 86. Astellas Pharma Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 87. Dr. Dunner Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 88. Kowa Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 89. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 90. Tianjin Tongrentang Group Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 91. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 92. Hunan Qianjin Xiang River Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 93. Kunming Jida Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 94. Jiangsu Lianhuan Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
    Figure 95. Bottom-up and Top-down Approaches for This Report
    Figure 96. Data Triangulation
    Figure 97. Key Executives Interviewed